BiomX is primarily focused on developing customised phage candidates that target and kill harmful bacteria. Credit: IBM Research/Flickr.

Israeli drug discovery firm BiomX has raised funds in a series B round to advance its lead acne and inflammatory bowel disease (IBD) drug programmes to the clinic.

The acne programme is set to start clinical trials by the end of this year, while the IBD programme is being planned for next year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The $32m equity financing was led by OrbiMed, Johnson & Johnson Innovation, Takeda Ventures, 8VC, MiraeAsset, Seventure Partners’ Health for Life Capital I, SBI Japan-Israel Innovation Fund as well as additional European investors.

In addition, the round was joined by RM Global Partners (RMGP) BioPharma Investment Fund, along with Chong Kun Dang Pharmaceutical, Handok, KB Investment and Consensus Business Group.

BiomX CEO Jonathan Solomon said: “The new funding will enable us to transition BiomX to a clinical stage company as our lead programmes in acne and IBD, both novel phage therapeutics targeting harmful bacteria in the microbiome, enter the clinic.

“The new funding will enable us to transition BiomX to a clinical stage company as our lead programmes in acne and IBD.”

BiomX is primarily focused on developing customised phage candidates that target and kill harmful bacteria causing chronic diseases such as IBD and cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Its acne drug candidate BX001 is a topical gel consisting of natural phage that could modulate Propionibacterium acnes (P. acnes).

Intended for IBD, BX002 is a customised phage cocktail designed to eliminate certain bacterial targets related to disease onset. This candidate is said to address the underlying cause of the condition, rather than providing only symptomatic relief.

The company forged multiple partnerships to aid in developing phage candidates.

With Takeda, BiomX is working on formulations for its phage therapy manufacturing intermediates and the final form to be administered.

In alliance with Janssen Pharmaceuticals, the company is using its XMarker biomarker discovery platform to stratify responders and non-responders to IBD therapeutics.

A deal with Weizmann Institute of Science provides access to phage discovery systems and target bacteria discovery platform, while JSR Corporation exclusively sub-licensed a set of bacterial targets for IBD.